Case report:Clinical manifestations and therapeutic options following rhTPO-induced neutralizing antibody production in a child with immune thrombocytopenia
- 4 November 2024
- journal article
- case report
- Published by Springer Nature in Annals of Hematology
- Vol. 103 (12) , 5941-5944
Abstract
Recombinant human thrombopoietin (rhTPO) is commonly used to improve low platelet status in immune thrombocytopenia (ITP), as one protein product, even witKeywords
This publication has 19 references indexed in Scilit:
- Recombinant human thrombopoietin (rhTPO) of different dosing regimens for refractory/relapsed primary immune thrombocytopenia: a multicenter, randomized controlled trial and pharmacokinetics studyPlatelets, 2023
- Modified recombinant human erythropoietin with potentially reduced immunogenicityScientific Reports, 2021
- Epidemiology and Clinical Manifestations of Immune ThrombocytopeniaHamostaseologie, 2019
- Incidence of childhood primary immune thrombocytopenic purpuraPediatrics International, 2015
- Clinical Findings With the First Generation of Thrombopoietic AgentsSeminars in Hematology, 2010
- Importance of biologic follow-ons: experience with EPOBest Practice & Research Clinical Haematology, 2005
- Multiple cycles of recombinant human thrombopoietin therapy in a patient with chronic refractory idiopathic thrombocytopenic purpuraBlood Coagulation & Fibrinolysis, 2005
- Recombinant human thrombopoietin: basic biology and evaluation of clinical studiesBlood, 2002
- Immune Thrombocytopenic PurpuraNew England Journal of Medicine, 2002
- ThrombopoietinNew England Journal of Medicine, 1998